Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug
- 14 June 2018
- journal article
- research article
- Published by Wiley in Angewandte Chemie
- Vol. 57 (29), 9098-9102
- https://doi.org/10.1002/anie.201804314
Abstract
Recently, Pt(IV) prodrugs have attracted much attention as the next generation of platinum‐based antineoplastic drug candidates. Here we report the discovery and evaluation of monochalcoplatin, a monocarboxylated Pt(IV) prodrug that is among the most active Pt(IV) prodrugs to date. Compared with its dicarboxylated counterpart chalcoplatin, monochalcoplatin astonishingly effectively and rapidly accumulates in cancer cells, which is not ascribed to its lipophilicity. The prodrug is quickly reduced, causes DNA damage, and induces apoptosis, resulting in superior cytotoxicity with IC50 values in the nanomolar range in both cisplatin‐sensitive and ‐resistant cells, which is up to 422‐fold higher than cisplatin. A detailed mechanistic study reveals that monochalcoplatin actively enters cells through a transporter‐mediated process. Moreover, monochalcoplatin shows significant antitumor activity in an in vivo colorectal tumor model. Our study implies a practical strategy for the design of more effective Pt(IV) prodrugs to conquer drug resistance by tuning both cellular uptake pathways and activation processes.Funding Information
- National Natural Science Foundation of China (21371145)
This publication has 36 references indexed in Scilit:
- Platinum(iv) anticancer prodrugs – hypotheses and factsDalton Transactions, 2016
- The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsChemical Reviews, 2016
- Glutathione boosting the cytotoxicity of a magnetic platinum(iv) nano-prodrug in tumor cellsChemical Science, 2016
- Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug DeliveryJournal of the American Chemical Society, 2014
- Immuno‐Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer AgentsAngewandte Chemie, 2014
- Immuno‐Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer AgentsAngewandte Chemie, 2014
- The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cellsChemical Communications, 2014
- The Prodrug Platin‐A: Simultaneous Release of Cisplatin and AspirinAngewandte Chemie, 2014
- Basis for Design and Development of Platinum(IV) Anticancer ComplexesJournal of Medicinal Chemistry, 2007
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005